Chiesi is a research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.
Our founder, Giacomo Chiesi, dreamed of driving cutting-edge research and founded the first Chiesi laboratory in Parma, Italy in 1935. Over 80 years later, Chiesi has become synonymous with delivering transformative solutions that change lives.
The UK arm of the global group was established in 1999, and has grown to a team of around 400 people based in our head office in Manchester, a research and development centre in Chippenham and a network of field-based teams.
We're proud supporters of the
NHS, and in 2023 alone, we supported educational events for
over 8,000 healthcare professionals.
We have been recognised as a UK Top Employer for over a
decade
We are committed to supporting
the communities in which we live
and work, and in 2023 alone, we
gave over 6,500 hours of volunteering.
In 2023, we invested 24% of our
global revenues into research and
development.
Patients are our purpose; they are at the centre of all our activities, processes, and decisions. Chiesi researches, develops and markets innovative solutions in three specific areas:
We operate against a shared value mission; making decision based on what is best for our business, patients, people and planet.
As a certified B Corp since 2019, we challenge ourselves in a process of continuous improvement, addressing high standards of externally-verified social and environmental commitments, public transparency, and legal accountability to balance profit and purpose.
Our values of integrity, inclusivity and trust underscore our identity and dedication to use our business as a force for good.
We supply medicines to over 100 countries worldwide, and we have a direct presence in 31. Our production operations are spread between Italy (Parma), France (Blois), and Brazil (Santana de Parnaiba).
The Chiesi Group’s main R&D activities are based in Parma in our new Biotech Centre of Excellence. The research in Parma is integrated with six other major hubs, in France, the United States, Canada, China, the United Kingdom and Sweden.
UK-CHI-2500018 | January 2025
